Risk Factors for Piperacillin-Tazobactam-Resistant Pseudomonas aeruginosa among Hospitalized Patients
Open Access
- 1 March 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (3) , 854-858
- https://doi.org/10.1128/aac.46.3.854-858.2002
Abstract
Antimicrobial resistance is an emerging problem with Pseudomonas aeruginosa. This study determined risk factors for the recovery of piperacillin-tazobactam-resistant P. aeruginosa from clinical cultures from hospitalized patients. A case-control study design was used to compare two groups of case patients with control patients. The first group of case patients was defined by nosocomial isolation of piperacillin-tazobactam-resistant P. aeruginosa, and the second group of cases yielded piperacillin-tazobactam-susceptible P. aeruginosa. Controls were selected in a 6:1 ratio from the same medical or surgical services among which piperacillin-tazobactam-resistant P. aeruginosa arose in patients. Risk factors analyzed included antimicrobial drug exposure, comorbid conditions, and demographics. Bivariate and multivariable analyses were performed. Piperacillin-tazobactam-resistant P. aeruginosa was isolated from 179 patients, and piperacillin-tazobactam-susceptible P. aeruginosa was isolated from 624 patients over a 2.5-year period. Piperacillin-tazobactam (odds ratio [OR] = 6.82; 95% confidence interval [CI], 4.56 to 10.21), imipenem (OR = 2.42; 95% CI, 1.19 to 4.94), aminoglycosides (OR = 2.18; 95% CI, 1.44 to 3.28), vancomycin (OR = 1.87; 95% CI, 1.21 to 2.89), and broad-spectrum cephalosporins (OR = 2.38; 95% CI, 1.45 to 3.88) were the antibiotics associated with the isolation of piperacillin-tazobactam-resistant P. aeruginosa. Exposure to vancomycin (OR = 1.53; 95% CI, 1.13 to 2.06) or ampicillin-sulbactam (OR = 2.28; 95% CI, 1.62 to 3.21) was associated with recovery of piperacillin-tazobactam-susceptible P. aeruginosa. In this study, antibiotics associated with piperacillin-tazobactam-susceptible P. aeruginosa were different from antibiotics associated with piperacillin-tazobactam-resistant P. aeruginosa. Piperacillin-tazobactam was a strong risk factor for piperacillin-tazobactam-resistant P. aeruginosa. Our results suggest that the nosocomial isolation of piperacillin-tazobactam-resistant P. aeruginosa may be affected by multiple antibiotics.Keywords
This publication has 15 references indexed in Scilit:
- Methodological Principles of Case-Control Studies That Analyzed Risk Factors for Antibiotic Resistance: A Systematic ReviewClinical Infectious Diseases, 2001
- Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized PatientsAntimicrobial Agents and Chemotherapy, 2000
- Risk Factors for Nosocomial Candiduria Due toCandida glabrataandCandida albicansClinical Infectious Diseases, 1999
- Vancomycin-Resistant Enterococci in Intensive Care UnitsArchives of internal medicine (1960), 1999
- Evolution and Dissemination of β-Lactamases Accelerated by Generations of β-Lactam AntibioticsClinical Infectious Diseases, 1997
- National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986–April 1996, issued May 1996American Journal of Infection Control, 1996
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- Epidemiology of Endemic Pseudomonas aeruginosa: Why Infection Control Efforts Have FailedThe Journal of Infectious Diseases, 1984
- Epidemiology of Infections Due to Pseudomonas aeruginosaClinical Infectious Diseases, 1984
- Antimicrobial Resistance in Hospital Organisms and Its Relation to Antibiotic UseClinical Infectious Diseases, 1983